Medincell and iM4TB Initiate Development of a Long-Acting Injectable Version of Macozinone, a Promising Investigational TB Treatment

22 April 2025

iM4TB, through its participation in ERA4TB – a European Union’s Horizon 2020 research and innovation program – is supporting initial development of a long-acting injectable (LAI) version of Macozinone, a potential new therapy for tuberculosis (TB)

LAI Macozinone could help address some of the biggest challenges in TB treatment: facilitating access, improving patient adherence even after symptoms subside, and lowering the risk of drug resistance

TB remains one of the deadliest diseases in history, still causes over 1.2 million deaths every year

iM4TB, Innovation Medicines for Tuberculosis, is a Swiss non-profit foundation dedicated to accelerating affordable TB treatments, backed by world-class partners like the Gates Foundation, and active in global collaborations especially in ERA4TB alongside leading organizations such as GSK, J&J, Evotec, TB Alliance, Universidad Carlos III de Madrid and the Pasteur Institute

Read the full press release here.